Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

[1]  A Gellert,et al.  Diagnosis of lung cancer by fibreoptic bronchoscopy: problems in the histological classification of non-small cell carcinomas. , 1984, Thorax.

[2]  S. Nakamura,et al.  Bronchial brushing and bronchial biopsy: comparison of diagnostic accuracy and cell typing reliability in lung cancer. , 1986, Thorax.

[3]  W F Whimster,et al.  How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. , 1993, Thorax.

[4]  D. Ettinger,et al.  Metastatic non-small cell lung cancer , 1993 .

[5]  A. J. Robertson,et al.  Observer variability in histopathological reporting of non-small cell lung carcinoma on bronchial biopsy specimens. , 1996, Journal of clinical pathology.

[6]  J. Padilla,et al.  Cell type accuracy of bronchial biopsy specimens in primary lung cancer. , 1996, Chest.

[7]  K. Kerr,et al.  Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category , 2000, Journal of clinical pathology.

[8]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Arber.  Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[10]  Atul C Mehta,et al.  Diagnosis of lung cancer: the guidelines. , 2003, Chest.

[11]  Douglas C McCrory,et al.  Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. , 2003, Chest.

[12]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[13]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[14]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Wilson,et al.  Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Spitz,et al.  Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  M Volante,et al.  ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[20]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[21]  Baorui Liu,et al.  ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel , 2008, BMC Cancer.

[22]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  William Pao,et al.  EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. , 2008, The Journal of molecular diagnostics : JMD.

[24]  Yuki Togashi,et al.  EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  D. Mavroudis,et al.  Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients , 2008, PloS one.

[26]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[27]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[28]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Voelkerding,et al.  Next-generation sequencing: from basic research to diagnostics. , 2009, Clinical chemistry.

[30]  G. Rossi,et al.  EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. , 2009, American journal of clinical pathology.

[31]  W. Pao,et al.  EML4-ALK: honing in on a new target in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Yoshizawa,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.

[33]  Yi-long Wu,et al.  Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression , 2010, Molecular Cancer.

[34]  K. Kerr,et al.  Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  K. Kerr,et al.  Guidelines on the radical management of patients with lung cancer , 2010, Thorax.

[36]  Michael Thomas,et al.  Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  Zhou Hai-yu.  Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression , 2010 .

[38]  Wang Yang.  DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy , 2010 .

[39]  A. Iafrate,et al.  A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry , 2010, Clinical Cancer Research.

[40]  T. Grogan,et al.  The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. , 2010, Methods.

[41]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[42]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[43]  W. Franklin,et al.  Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment , 2010, Clinical Cancer Research.

[44]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[45]  M. Cronin,et al.  Whole cancer genome sequencing by next-generation methods. , 2011, American journal of clinical pathology.

[46]  A. Iafrate,et al.  A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. , 2011, The Journal of molecular diagnostics : JMD.

[47]  Mattia Barbareschi,et al.  Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine‐needle aspiration cytology , 2011, Cancer.

[48]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[49]  P. Maxwell,et al.  BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. , 2011, Gynecologic oncology.

[50]  Helen M. Moore,et al.  Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. , 2011, Archives of pathology & laboratory medicine.

[51]  Sanjay Mukhopadhyay,et al.  Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy Specimens: Utility of an Immunohistochemical Panel Containing TTF-1, Napsin A, p63, and CK5/6 , 2011, The American journal of surgical pathology.

[52]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[53]  Hyojin Kim,et al.  Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[54]  P. Hamilton,et al.  PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer , 2011, The Journal of pathology.

[55]  D. Rassl,et al.  Accuracy of cell typing in nonsmall cell lung cancer by EBUS/EUS–FNA cytological samples , 2011, European Respiratory Journal.

[56]  Ping Yang,et al.  Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[57]  M. Dietel,et al.  EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations , 2012, Virchows Archiv.

[58]  L. Bubendorf,et al.  The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. , 2012, Lung cancer.

[59]  S. Tripp,et al.  Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optima , 2012, Archives of pathology & laboratory medicine.

[60]  G. Hampton,et al.  Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib , 2011, Clinical Cancer Research.

[61]  K. Kerr.  Personalized medicine for lung cancer: new challenges for pathology , 2012, Histopathology.

[62]  D. Mavroudis,et al.  ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  M. Ladanyi,et al.  ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[64]  S. Raab.  Optimal Immunohistochemical Markers for Distinguishing Lung Adenocarcinomas From Squamous Cell Carcinomas in Small Tumor Samples , 2012 .

[65]  Sung-Liang Yu,et al.  Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Giuseppe Pelosi,et al.  p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma , 2012, Modern Pathology.

[67]  A. Marchetti,et al.  Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing , 2012, Clinical Cancer Research.

[68]  H. Ji,et al.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Yuval Kluger,et al.  Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. , 2012, Journal of the National Cancer Institute.

[70]  H. Pass,et al.  BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma , 2012, The Journal of pathology.

[71]  M. L. R. D. Christenson,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2012 .

[72]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[73]  A. Marchetti,et al.  Guideline on the requirements of external quality assessment programs in molecular pathology , 2012, Virchows Archiv.

[74]  J. Orenstein,et al.  Revolution in lung cancer: new challenges for the surgical pathologist. , 2012, Archives of pathology & laboratory medicine.

[75]  A. Tsao,et al.  ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .

[76]  Dong-Wan Kim,et al.  Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. , 2012, Lung cancer.

[77]  F. Cappuzzo,et al.  Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[78]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[79]  A. Marchetti,et al.  Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[80]  J. Pignon,et al.  ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. , 2013, The New England journal of medicine.

[81]  David R. Chafin,et al.  Rapid Two-Temperature Formalin Fixation , 2013, PloS one.

[82]  N. Normanno,et al.  European consensus conference for external quality assessment in molecular pathology. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  J. Mosser,et al.  Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). , 2013 .

[84]  Tuan S. Nguyen,et al.  Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[85]  G. Bepler,et al.  Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  David L Rimm,et al.  Delay to formalin fixation ‘cold ischemia time’: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry , 2013, Modern Pathology.

[87]  A. Nicholson,et al.  Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. , 2013, Archives of pathology & laboratory medicine.

[88]  A. Dejmek,et al.  Preparation of DNA from cytological material , 2013, Cancer cytopathology.

[89]  K. Kerr,et al.  Pathology and personalized medicine in lung cancer , 2013 .

[90]  A. McCullough.  Comprehensive genomic characterization of squamous cell lung cancers , 2013 .

[91]  Niruthika Sritharan,et al.  Genomic landscape of non-small-cell lung cancer in smokers and never-smokers , 2013, Thorax.

[92]  B. Johnson,et al.  The impact of genomic changes on treatment of lung cancer. , 2013, American journal of respiratory and critical care medicine.

[93]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.

[94]  C. Rudin,et al.  Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. , 2013 .

[95]  H. Adami,et al.  European Consensus Conference for external quality assessment in molecular pathology , 2013 .

[96]  L. Bubendorf,et al.  Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[97]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  R. Rosenfeld.  Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.